Acute Pyelonephritis. Urinary tract infection, site not specified
Conditions
Interventions
Intervention 1: Vitamin A group: Keflin or Ampicillin 100mg/kg/day qid and Amikacin 15mg/kg/day, tid for 10 days, as well as vitamin A, 1500 U/kg/day for 10 days. Intervention 2: Control group: Keflin
Treatment - Drugs
Vitamin A group: Keflin or Ampicillin 100mg/kg/day qid and Amikacin 15mg/kg/day, tid for 10 days, as well as vitamin A, 1500 U/kg/day for 10 days
Control group: Keflin or Ampicillin 100mg/kg/day qid as well as Amikacin 15mg/kg/day, tid for 10 days, or appropriate to antibiogram if it is available
Vitamin E group: A group: Keflin or Ampicillin 100mg/kg/day qid and Amikacin 15mg/kg/day, tid for 10 days, as well as vitamin E 15-25U/day, for 10 days
Sponsors
Tehran University of Medical sciences
Eligibility
Sex/Gender
All
Age
1 Years to 10 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: positive urine culture, clinical findings, and 99mTC-DMSA criteria of APN Exclusion criteria: presence of neurogenic bladder, systemic hypertension, obstructive uropathy, high grade vesico-ureteral reflux (Grade 4-5)
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Renal scar. Timepoint: at least 6 month apart. Method of measurement: Criteria of developing scar in 99mTC-DMSA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Intolerance to vitamins. Timepoint: daily. Method of measurement: daily clinical observation.;No response to antibiotic thepay. Timepoint: daily. Method of measurement: urine culture at the 3rd day, clinical observation for fever and general condition.;Acute renal failure. Timepoint: daily at the time of hospitalization. Method of measurement: urine output, serum creatinine, blood pressure measuement. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactBehnam Sobooti
Tehran University of Medical Sciences
Outcome results
None listed